SVR12 Rate of 96.2% in 209 HCV Genotype 1-infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin

Press/Media: Press / Media

PeriodDec 16 2014

Media coverage

1

Media coverage

  • TitleSVR12 Rate of 96.2% in 209 HCV Genotype 1-infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date12/16/14
    PersonsFred Poordad